ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Quite frequently, imatinib will be the first choice when treating CML and will be changed to a second-generation BCR-ABL inhibitor if the disease progresses or if the patient presents intolerance to imatinib [4].